Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Fontein, D.B.Y., Seynaeve, C., Hadji, P., Hille, E.T.M., van de Water, W., Putter, H., Kranenbarg, E.M.-K., Hasenburg, A., Paridaens, R.J., Vannetzel, J.-M., Markopoulos, C., Hozumi, Y., Bartlett, J.M.S., Jones, S.E., Rea, D.W., Nortier, J.W.R., van de Velde, C.J.H., 2013.

J Clin Oncol 31, 2257–2264. doi:10.1200/JCO.2012.45.3068

Studie: TEAM; Indikation: Mammakarzinom; Jahr: 2013; Veranstaltung: -; Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com